iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery
AIM: To enhance the tumor accumulation and targeted drug delivery for colon cancer therapy, iRGD peptide was introduced to the surface of PEGylated camptothecin-loaded nanoparticles (NPs).
METHODS: Cellular uptake, targeting specificity, biodistribution and antitumor capacity were evaluated.
RESULTS: The functionalization of iRGD facilitated tumor accumulation and cellular uptake of NPs by Colon-26 cells. Furthermore, the resultant iRGD-PEG-NPs remarkably improved the therapeutic efficacy of camptothecin in vitro and in vivo by inducing a higher degree of tumor cell apoptosis compared with PEG-NPs.
CONCLUSION: iRGD-PEG-NP is a desired drug delivery system to facilitate the drug accumulation in orthotopic colon tumor tissues and further drug internalization by colon cancer cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 12(2017), 16 vom: 13. Aug., Seite 1991-2006 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Lijun [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.09.2018 Date Revised 13.11.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2017-0107 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM274198169 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM274198169 | ||
| 003 | DE-627 | ||
| 005 | 20231225002939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2017-0107 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0914.xml |
| 035 | |a (DE-627)NLM274198169 | ||
| 035 | |a (NLM)28745123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Lijun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.09.2018 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: To enhance the tumor accumulation and targeted drug delivery for colon cancer therapy, iRGD peptide was introduced to the surface of PEGylated camptothecin-loaded nanoparticles (NPs) | ||
| 520 | |a METHODS: Cellular uptake, targeting specificity, biodistribution and antitumor capacity were evaluated | ||
| 520 | |a RESULTS: The functionalization of iRGD facilitated tumor accumulation and cellular uptake of NPs by Colon-26 cells. Furthermore, the resultant iRGD-PEG-NPs remarkably improved the therapeutic efficacy of camptothecin in vitro and in vivo by inducing a higher degree of tumor cell apoptosis compared with PEG-NPs | ||
| 520 | |a CONCLUSION: iRGD-PEG-NP is a desired drug delivery system to facilitate the drug accumulation in orthotopic colon tumor tissues and further drug internalization by colon cancer cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PEGylated nanoparticle | |
| 650 | 4 | |a active targeting | |
| 650 | 4 | |a iRGD peptide | |
| 650 | 4 | |a orthotopic colon cancer | |
| 650 | 4 | |a tumor accumulation | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a N-end cysteine peptide tumor-homing peptide |2 NLM | |
| 650 | 7 | |a Oligopeptides |2 NLM | |
| 650 | 7 | |a Polyglycolic Acid |2 NLM | |
| 650 | 7 | |a 26009-03-0 |2 NLM | |
| 650 | 7 | |a Camptothecin |2 NLM | |
| 650 | 7 | |a XT3Z54Z28A |2 NLM | |
| 700 | 1 | |a Chen, Qiubing |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Panpan |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Moon Kwon |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Zhigang |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Yuejun |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Merlin, Didier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 12(2017), 16 vom: 13. Aug., Seite 1991-2006 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2017 |g number:16 |g day:13 |g month:08 |g pages:1991-2006 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2017-0107 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2017 |e 16 |b 13 |c 08 |h 1991-2006 | ||